Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2026-05-06 16:15:49 ET · period of report 2026-05-04 · accession 0002050167-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-06 16:15 | 2026-05-04 | MAZE | Dandekar Atul | CSBO | M - OptEx | $10.42 | +14.3K | 24.8K | +136% | +$149.1K |
| DM | 2026-05-06 16:15 | 2026-05-04 | MAZE | Dandekar Atul | CSBO | M - OptEx | $0.00 | -14.3K | 27.7K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-04 | M | A | 8,320 | $10.42 | 18,823 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-04 | M | A | 5,985 | $10.42 | 24,808 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-05-04 | M | D | 8,320 | $0.00 | 20,204 | D | $10.42 · — to 2032-03-15 | 8,320 Common Stock | (F1) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-05-04 | M | D | 5,985 | $0.00 | 27,725 | D | $10.42 · — to 2033-03-03 | 5,985 Common Stock | (F2) The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |